Novartis reported sales for its Alcon eye care business of $1.4 billion in the first quarter, down by 1 percent versus last year's first quarter. In constant currencies, Alcon sales increased by 1 percent. Novartis said Alcon's growth plan is on track, with ongoing actions to accelerate sales and innovation, ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
To continue reading this article register now.